Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds.

Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.

Methods for preparing compounds having the following structure (I): ##STR00001##
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.4c, are as defined herein are provided. Related compounds and methods for making the same are also provided.

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.

Crystalline forms of anamorelin which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.

The present invention relates to a process for preparing substituted anthranilic acid derivatives of the formula (I) ##STR00001##
in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each as defined in the description, by conversion of compounds of the general formula (IV) in the presence of a palladium catalyst and carbon monoxide. The present invention likewise relates to compounds of the general formula (IV). ##STR00002##

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

The present invention relates spiro-cyclic amine derivatives of the formula (1) wherein R1; R2; R3; Q; W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor (s) is (are) involved. ##STR00001##

Malonic ester derivatives of the formula (I) ##STR00001##
in which the symbols A.sup.1, A.sup.2, Y, R.sup.10, p, X, R.sup.2, G, Q, L.sup.2 and R.sup.1 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).

The present invention relates to tackifier compounds and methods of using the same. In various embodiments, the present invention provides a tackifier compound including independently substituted or unsubstituted fused rings A and B each independently chosen from (C.sub.5-C.sub.10)cycloalkyl and (C.sub.2-C.sub.10)heterocyclyl. Fused ring A is substituted with (R.sup.1).sub.1-8 and fused ring B is substituted with (OC(O)RC(O)R.sup.2).sub.1-8. At each occurrence R is independently chosen from (C.sub.2-C.sub.10)alkanylene, (C.sub.2-C.sub.10)alkenylene, (C.sub.2-C.sub.10)alkynylene, C.sub.5-C.sub.20(arylene), and (C.sub.1-C.sub.20)heteroarylene, wherein R is unsubstituted or substituted. At each occurrence R.sup.1 is independently selected from OH, OR.sup.3, and OC(O)RC(O)R.sup.2. At each occurrence R.sup.2 is independently chosen from OH, OR.sup.3, NH.sub.2, NHR.sup.3, and NR.sup.3.sub.2. At each occurrence R.sup.3 is independently chosen from (C.sub.1-C.sub.10)alkanyl, (C.sub.2-C.sub.10)alkenyl, (C.sub.2-C.sub.10)alkynyl, C.sub.5-C.sub.20(aryl), and (C.sub.1-C.sub.20)heteroaryl, wherein R.sup.3 is unsubstituted or substituted.